Electra Therapeutics, Inc.

Electra Therapeutics, Inc. (ETRA) priced its initial public offering on Sep 18, 2026 at $15.00 per share, within its $14.00–$16.00 range, raising $350M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $941.5M. Jefferies was lead-left underwriter, joined by TD Cowen, Evercore ISI and Cantor. Cooley advised the company and Latham & Watkins advised the underwriters.

Electra Therapeutics, Inc. is a late clinical-stage biopharmaceutical company developing precision medicines for immune-mediated diseases and cancer by targeting signal regulatory proteins (SIRP), to selectively deplete disease-driving cells while preserving normal immune function.

Status

IPO

Ticker

ETRA

Exchange

Nasdaq Global Select

Priced

Sep 18, 2026

IPO price

$15.00

Price range

$14.00–$16.00

Raised

$350M

Market cap at IPO price

$941.5M

First filed

Aug 28, 2026

Underwriters

Jefferies, TD Cowen, Evercore ISI and Cantor

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.